Donor immune-cell therapy for stubborn adenovirus infections
Part of Infections clinical trials.
This study tests whether specially matched donor T-cells can control “refractory” adenovirus (a virus) that isn’t responding to usual antiviral medicines. It may help if the infection keeps coming back or is already affecting organs like the lungs or bowel.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between birth and 60 years old
- You have a condition linked to weaker immune protection (for example: recent organ transplant, cancer with recent chemotherapy, immune disorders, or recent immune-suppressing medicines)
- You must have adenovirus that is hard to treat, such as virus in the blood or symptoms affecting organs despite antivirals for at least 14 days
- If you can become pregnant, you must have a negative pregnancy test and use reliable birth control; no breastfeeding
- You (or your parent/guardian) must be able to sign informed consent/assent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether directly infusing donor-made immune cells (virus-fighting T-cells) is safe and feasible in people who still have viral infections after a stem cell transplant. It may help your body control infections from adenovirus, CMV, or EBV when standard antiviral treatments aren’t working.
This trial tests a custom immune cell treatment (T cells made to recognize adenovirus) for people whose adenovirus infection is not improving or who cannot tolerate standard antiviral medicines after a bone marrow transplant. It aims to help your body control the virus and prevent organ complications.
This early-phase study tests donor immune cells made to recognize CMV (a virus) or adenovirus, given to help control virus reactivation after a solid organ or bone marrow transplant. It may help reduce ongoing or worsening viral infection when standard antiviral medicines are hard to tolerate or not working well.
This Phase 2 study tests donor-made immune T-cells that specifically target viruses to treat or prevent viral infections after a stem cell transplant. It may help your body control dangerous viruses like adenovirus, CMV, EBV, and BK virus, while checking safety with different timing of the treatment.
This trial tests a personalized immune cell treatment (CMV-specific T cells) for people whose CMV (a common herpes virus) persists or comes back after a stem cell transplant. It may help your immune system better control CMV when standard antiviral medicines aren’t fully working or can’t be used.
This trial tests a special immune-cell treatment made to fight adenovirus in people whose adenovirus infection keeps coming back or won’t improve after transplant. It may help control infection when standard antiviral medicines are not working or can’t be tolerated.
Hear when a new Adenovirus Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.